# Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

> **NCT00216450** · PHASE4 · COMPLETED · sponsor: **Janssen Cilag Pharmaceutica S.A.C.I., Greece** · enrollment: 80 (actual)

## Conditions studied

- Helicobacter Infections
- Bacterial Infections

## Interventions

- **DRUG:** rabeprazole sodium

## Key facts

- **NCT ID:** NCT00216450
- **Lead sponsor:** Janssen Cilag Pharmaceutica S.A.C.I., Greece
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2010-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216450, "Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00216450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*